IMAJ | volume 25
Journal 1, January 2023
Salmonella Bloodstream Infection Secondary to Treatment with Baricitinib in COVID-19
1 Department of Internal Medicine, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Israel
2 Departments of Clinical Microbiology and Infectious Diseases, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Israel
Coronavirus disease 2019 (COVID-19), first identified in 2019, constitutes a global major public health burden. Most of morbidity and mortality is derived by the severe inflammatory reaction (cytokine release syndrome) that ensues in later stages. Baricitinib, a selective JAK inhibitor primarily used for the treatment of rheumatoid arthritis (RA) , was shown to reduce mortality in COVID-19 hospitalized patients in combination with remdesivir .